Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

[1]  C. Ustun,et al.  Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. , 2008, Clinical therapeutics.

[2]  Richard Pazdur,et al.  Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib , 2008, Clinical Cancer Research.

[3]  K. Bhalla,et al.  Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[5]  J. Mestan,et al.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL , 2006, British Journal of Cancer.

[6]  V. Fischer,et al.  Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects. , 2005 .

[7]  Z. Estrov,et al.  AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells , 2005, Cancer.

[8]  J. Mestan,et al.  AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia , 2005, Clinical Cancer Research.

[9]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[10]  Vera Mihajlovic‐Madzarevic,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, JAMA.

[11]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[12]  V. Rodighiero.  Effects of Liver Disease on Pharmacokinetics , 1999, Clinical pharmacokinetics.

[13]  D. Morgan,et al.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver Disease , 1995, Clinical pharmacokinetics.

[14]  B. Bégaud,et al.  Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis , 1991, Clinical pharmacology and therapeutics.

[15]  D. Harron.  Clinical pharmacokinetics: Concepts and applications (2nd edn.) , 1989 .

[16]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[17]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[18]  P. Palatini,et al.  Effect of moderate or severe liver dysfunction on the pharmacokinetics of γ-hydroxybutyric acid , 1996, European Journal of Clinical Pharmacology.

[19]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[20]  C. G. Child,et al.  The liver and portal hypertension , 1964 .

[21]  C. G. Child,et al.  Surgery and portal hypertension. , 1964, Major problems in clinical surgery.